Skip to main content

Advertisement

Table 6 Per-protocol analysis of change in prescribing rates, showing sum scores per clinical topic and drug

From: Effect of audit and feedback with peer review on general practitioners’ prescribing and test ordering performance: a cluster-randomized controlled trial

  Intervention Control  
Clinical topic N Mean before (sd) Mean after (sd) n Mean before (sd) Mean after (sd) Ba (95% CI) icc Direction p
Anaemia
 Iron preparations. oral 35 29.5 (22.5) 38.7 (25.6) 53 26.6 (27.6) 46.9 (54.2) 18.9 (−3.9, 41.7) 0.43 = 0.098
Urinary tract infections
 Antibiotics UTI 8 40.8 (24.0) 44.5 (29.7) 80 46.5 (36.3) 55.3 (44.8) 6.3 (−21.1, 33.8) 0.33 0.623
 Prostate complaints 26 68.5 (47.0) 79.5 (63.0) 62 65.5 (53.6) 125.9 (91.9) 28.5 (6.5, 50.7) 0.27 0.016
 Alpha receptor blockers 26 57.5 (41.1) 66.5 (54.2) 62 54.0 (44.9) 101.5 (73.2) 44.2 (6.0, 82.3) 0.49 0.027
 5 alpha reductase inhibitors 26 11.0 (7.5) 13.0 (11.7) 62 11.5 (11.0) 24.5 (22.9) 11.1 (2.1, 20.2) 0.05 0.020
 Stomach complaints 28 455.1 (294.7) 565.2 (303.7) 60 275.7 (253.8) 509.1 (433.0) 61.1 (15.0, 107.2) 0.11 0.014 b
 H2 antagonists 28 28.0 (22.4) 32.4 (26.8) 60 23.2 (22.35) 24.2 (22.6) −2.4 (−21.5, 16.7) 0.68 0.788
 Proton pump inhibitors 28 425.9 (276.1) 531.5 (283.8) 60 251.6 (234.0) 483.7 (414.7) 254.8 (60.1, 449.5) 0.66 0.014 b
 Misoprostol 28 0 (0) 0 (0) 60 0.1 (0.4) 0.1 (0.45) 0.1 (−0.1, 0.2) 0.01 0.365
 Triple therapy (ATC A02BD04) 28 1.2 (2.5) 1.4 (1.8) 60 0.9 (1.2) 1.1 (1.6) 0.1 (−0.7, 0.8) 0.20 0.878b
 Thyroid dysfunction 29 82.2 (45.9) 99.2 (57.5) 59 86.0 (63.1) 128.5 (94.6) 12.6 (0.7, 24.4) 0.08 = 0.040
 Thyroid hormones 29 76.7 (43.5) 91.1 (52.2) 59 79.5 (58.8) 118.3 (87.8) 25.2 (2.1, 48.3) 0.19 = 0.035
 Antithyroid preparations 29 5.5 (7.4) 8.2 (13.2) 59 6.5 (7.7) 10.1 (14.0) 0.2 (−4.2, 4.6) 0.11 0.927
Perimenopausal complaints 24 59.4 (31.9) 56.5 (25.9) 64 51.2 (40.0) 51.3 (40.0) 1.5 (−2.3, 5.4) 0.21 0.414
 Oestrogens. oral 24 11.5 (8.0) 9.7 (6.2) 64 14.0 (14.0) 12.3 (12.4) 1.0 (−3.6, 5.5) 0.03 0.612
 Contraceptives (>50y) 24 5.1 (2.8) 5.9 (2.7) 64 3.2 (3.6) 6.5 (5.1) 2.5 (−0.9, 5.8) 0.31 0.137
 Hormone replacement therapy 24 38.7 (24.2) 36.3 (21.0) 64 31.1 (24.4) 29.8 (24.4) 2.6 (−9.7, 14.9) 0.60 0.652
 Clonidine 24 0.6 (1.5) 0.7 (2.7) 64 0.4 (1.5) 0.4 (1.6) −0.3 (−1.4, 0.7) 0.11 0.508 b
 Tibolon 24 3.6 (3.7) 3.8 (4.1) 64 2.6 (3.0) 2.3 (3.3) −0.7 (−2.0, 0.6) 0.00 0.294 b
  1. The desired direction of change is given in the column headed ‘Direction’. Numbers represent the number of DDDs prescribed per 6 months per 1000 patients
  2. n = number of practices
  3. aAdjusted difference between groups at end of intervention, corrected for baseline
  4. bStatistically significant interaction
  5. Thyroid dysfunctioning: Clonidine
  6. P10: B (95% CI): 30.3 (15.1, 45.5). p: <0.001 P10: B (95% CI): 0.4 (−0.4, 1.2). p: 0.327
  7. P90: B (95% CI): 186.7 (88.7, 284.7). p: <0.001 P90: B (95% CI):−1.3 (−2.2,−0.4). p: 0.005
  8. Stomach complaints: Tibolon
  9. P10: B (95% CI): 1.4 (−39.6, 42.6). p: 0.937 P10: B (95% CI): 0.9 (−0.8, 2.6). p: 0.297
  10. P90: B (95% CI): 408.8 (341.1, 476.5). p: <0.001 P90: B (95% CI):−2.3 (−4.0,−0.6). p: 0.008
  11. PPIs: Triple therapy (ATC A02BD04)
  12. P10: B (95% CI): 91.5 (−120.0, 303.0). p: 0.378 P10: B (95% CI):−0.8 (−1.9, 0.3). p: 0.133
  13. P90: B (95% CI): 347.4 (159.2, 0.8). p: <0.001 P90: B (95% CI): 1.4 (0.3, 2.5). p: 0.014